TenBroek E, Yunker L, Nies M, Bendele A. Randomized controlled studies on the efficacy of antiarthritic agents in inhibiting cartilage degeneration and pain associated with progression of osteoarthritis in the rat. Arthritis Res Ther. 2016;18:24 pubmed publisher

Katoumas K, Nikitakis N, Perrea D, Dontas I, Sklavounou A. In Vivo Antineoplastic Effects of the NSAID Sulindac in an Oral Carcinogenesis Model. Cancer Prev Res (Phila). 2015;8:642-9 pubmed publisher

Liu W, Lirio S, Yang Y, Wu L, Hsiao S, Huang H. A poly(alkyl methacrylate-divinylbenzene-vinylbenzyl trimethylammonium chloride) monolithic column for solid-phase microextraction. J Chromatogr A. 2015;1395:32-40 pubmed publisher

Shimizu M, Shiraishi A, Sato A, Nagashima S, Yamazaki H. Potential for drug interactions mediated by polymorphic flavin-containing monooxygenase 3 in human livers. Drug Metab Pharmacokinet. 2015;30:70-4 pubmed publisher

Zhou X, Li Y, Gao S, Wang X, Wang P, Yan Y, et al. Sulindac has strong antifibrotic effects by suppressing STAT3-related miR-21. J Cell Mol Med. 2015;19:1103-13 pubmed publisher

Majcher A, Lewandrowska A, Herold F, Stefanowicz J, Słowiński T, Mazurek A, et al. A method for rapid screening of interactions of pharmacologically active compounds with albumin. Anal Chim Acta. 2015;855:51-9 pubmed publisher

Cousido Siah A, Ruiz F, Crespo I, Porté S, Mitschler A, Parés X, et al. Structural analysis of sulindac as an inhibitor of aldose reductase and AKR1B10. Chem Biol Interact. 2015;234:290-6 pubmed publisher

Fink S, Dawson D, Zhang Y, Kresak A, Lawrence E, Yang P, et al. Sulindac reversal of 15-PGDH-mediated resistance to colon tumor chemoprevention with NSAIDs. Carcinogenesis. 2015;36:291-8 pubmed publisher

Pacelli S, Paolicelli P, Dreesen I, Kobayashi S, Vitalone A, Casadei M. Injectable and photocross-linkable gels based on gellan gum methacrylate: a new tool for biomedical application. Int J Biol Macromol. 2015;72:1335-42 pubmed publisher

Fu Z, Aucoin D, Ahmed M, Ziliox M, Van Nostrand W, Smith S. Capping of aβ42 oligomers by small molecule inhibitors. Biochemistry. 2014;53:7893-903 pubmed publisher

Sur A, Kesaraju S, Prentice H, Ayyanathan K, Baronas Lowell D, Zhu D, et al. Pharmacological protection of retinal pigmented epithelial cells by sulindac involves PPAR-α. Proc Natl Acad Sci U S A. 2014;111:16754-9 pubmed publisher

Zhang Y, Yang C, Yuan G, Wang Z, Cui W, Li R. Sulindac attenuates valproic acid-induced oxidative stress levels in primary cultured cortical neurons and ameliorates repetitive/stereotypic-like movement disorders in Wistar rats prenatally exposed to valproic acid. Int J Mol Med. 2015;35:263-70 pubmed publisher

Leibowitz B, Qiu W, Buchanan M, Zou F, Vernon P, Moyer M, et al. BID mediates selective killing of APC-deficient cells in intestinal tumor suppression by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci U S A. 2014;111:16520-5 pubmed publisher

Kamath Rayne B, Habli M, Rodriguez Z, Wu M, Gresh J, DeFranco E. Antenatal exposure to sulindac and risk of necrotizing enterocolitis. Am J Obstet Gynecol. 2015;212:96.e1-7 pubmed publisher

Modi J, Gharibani P, Ma Z, Tao R, Menzie J, Prentice H, et al. Protective mechanism of sulindac in an animal model of ischemic stroke. Brain Res. 2014;1576:91-9 pubmed publisher

Apschner A, Huitema L, Ponsioen B, Peterson Maduro J, Schulte Merker S. Zebrafish enpp1 mutants exhibit pathological mineralization, mimicking features of generalized arterial calcification of infancy (GACI) and pseudoxanthoma elasticum (PXE). Dis Model Mech. 2014;7:811-22 pubmed publisher

Yamazaki M, Shimizu M, Uno Y, Yamazaki H. Drug oxygenation activities mediated by liver microsomal flavin-containing monooxygenases 1 and 3 in humans, monkeys, rats, and minipigs. Biochem Pharmacol. 2014;90:159-65 pubmed publisher

Wu Z, Chen X, Liu F, Chen W, Wu P, Wieschhaus A, et al. Calpain-1 contributes to IgE-mediated mast cell activation. J Immunol. 2014;192:5130-9 pubmed publisher

Xia M, Zhu Y. Fibronectin enhances spinal cord astrocyte proliferation by elevating P2Y1 receptor expression. J Neurosci Res. 2014;92:1078-90 pubmed publisher

Liggett J, Zhang X, Eling T, Baek S. Anti-tumor activity of non-steroidal anti-inflammatory drugs: cyclooxygenase-independent targets. Cancer Lett. 2014;346:217-24 pubmed publisher

Guadalupe Sánchez González E, Yepez Mulia L, Jesús Hernández Abad V, Jung Cook H. The influence of polymorphism on the manufacturability and in vitro dissolution of sulindac-containing hard gelatin capsules. Pharm Dev Technol. 2015;20:306-13 pubmed publisher

Lee Y, Choi D, Kim N, Yang S, Jung E, Hong M, et al. CXCR2 inhibition enhances sulindac-mediated suppression of colon cancer development. Int J Cancer. 2014;135:232-7 pubmed publisher

Mladenova D, Pangon L, Currey N, Ng I, Musgrove E, Grey S, et al. Sulindac activates NF-?B signaling in colon cancer cells. Cell Commun Signal. 2013;11:73 pubmed publisher

Liggett J, Choi C, Donnell R, Kihm K, Kim J, Min K, et al. Nonsteroidal anti-inflammatory drug sulindac sulfide suppresses structural protein Nesprin-2 expression in colorectal cancer cells. Biochim Biophys Acta. 2014;1840:322-31 pubmed publisher

Martin J, Young G, Le Leu R, Hu Y. Comparing the effects of COX and non-COX-inhibiting NSAIDs on enhancement of apoptosis and inhibition of aberrant crypt foci formation in a rat colorectal cancer model. Anticancer Res. 2013;33:3581-8 pubmed

Greening D, Ji H, Kapp E, Simpson R. Sulindac modulates secreted protein expression from LIM1215 colon carcinoma cells prior to apoptosis. Biochim Biophys Acta. 2013;1834:2293-307 pubmed publisher

Li H, Yang A, Chung Y, Zhang W, Liao J, Yang G. Sulindac inhibits pancreatic carcinogenesis in LSL-KrasG12D-LSL-Trp53R172H-Pdx-1-Cre mice via suppressing aldo-keto reductase family 1B10 (AKR1B10). Carcinogenesis. 2013;34:2090-8 pubmed publisher

. Trying times for generic medicines in the USA. Lancet. 2013;381:1072 pubmed publisher

Raj K, Zell J, Rock C, McLaren C, Zoumas Morse C, Gerner E, et al. Role of dietary polyamines in a phase III clinical trial of difluoromethylornithine (DFMO) and sulindac for prevention of sporadic colorectal adenomas. Br J Cancer. 2013;108:512-8 pubmed publisher

Bi X, Pohl N, Dong H, Yang W. Selenium and sulindac are synergistic to inhibit intestinal tumorigenesis in Apc/p21 mice. J Hematol Oncol. 2013;6:8 pubmed publisher

Skapek S, Anderson J, Hill D, Henry D, Spunt S, Meyer W, et al. Safety and efficacy of high-dose tamoxifen and sulindac for desmoid tumor in children: results of a Children's Oncology Group (COG) phase II study. Pediatr Blood Cancer. 2013;60:1108-12 pubmed publisher

Chaudhary S, Singh T, Kapur P, Weng Z, Arumugam A, Elmets C, et al. Nitric oxide-releasing sulindac is a novel skin cancer chemopreventive agent for UVB-induced photocarcinogenesis. Toxicol Appl Pharmacol. 2013;268:249-55 pubmed publisher

Limburg P, Mandrekar S, Aubry M, Ziegler K, Zhang J, Yi J, et al. Randomized phase II trial of sulindac for lung cancer chemoprevention. Lung Cancer. 2013;79:254-61 pubmed publisher

Zbidah M, Lupescu A, Yang W, Bosc A, Jilani K, Shaik N, et al. Sulindac sulfide--induced stimulation of eryptosis. Cell Physiol Biochem. 2012;30:1072-82 pubmed publisher

Castrignanò S, Sadeghi S, Gilardi G. Entrapment of human flavin-containing monooxygenase 3 in the presence of gold nanoparticles: TEM, FTIR and electrocatalysis. Biochim Biophys Acta. 2012;1820:2072-8 pubmed publisher

Xing Y, Zhang X, Zhao K, Cui L, Wang L, Dong L, et al. Beneficial effects of sulindac in focal cerebral ischemia: a positive role in Wnt/β-catenin pathway. Brain Res. 2012;1482:71-80 pubmed publisher

Chennamaneni S, Zhong B, Lama R, Su B. COX inhibitors Indomethacin and Sulindac derivatives as antiproliferative agents: synthesis, biological evaluation, and mechanism investigation. Eur J Med Chem. 2012;56:17-29 pubmed publisher

Watahiki H, Yagishita S, Futai E, Ishiura S. CTF1-51, a truncated carboxyl-terminal fragment of amyloid precursor protein, suppresses the effects of Aβ42-lowering γ-secretase modulators. Neurosci Lett. 2012;526:96-9 pubmed publisher

Flanagan J, Yosaatmadja Y, Teague R, Chai M, Turnbull A, Squire C. Crystal structures of three classes of non-steroidal anti-inflammatory drugs in complex with aldo-keto reductase 1C3. PLoS ONE. 2012;7:e43965 pubmed publisher

Rial N, Zell J, Cohen A, Gerner E. Clinical end points for developing pharmaceuticals to manage patients with a sporadic or genetic risk of colorectal cancer. Expert Rev Gastroenterol Hepatol. 2012;6:507-17 pubmed publisher

Bai H, Chen X, Zhang L, Dou X. The effect of sulindac, a non-steroidal anti-inflammatory drug, attenuates inflammation and fibrosis in a mouse model of chronic pancreatitis. BMC Gastroenterol. 2012;12:115 pubmed publisher

Neiburger E. Jaded smiles: ancient Mayan dental inlays and today's Central American patients. J Mass Dent Soc. 2012;60:36-9 pubmed

Zell J, Lin B, Madson N, McLaren C, Gerner E, Meyskens F. Role of obesity in a randomized placebo-controlled trial of difluoromethylornithine (DFMO) + sulindac for the prevention of sporadic colorectal adenomas. Cancer Causes Control. 2012;23:1739-44 pubmed publisher

Hillion J, Smail S, Di Cello F, Belton A, Shah S, Huso T, et al. The HMGA1-COX-2 axis: a key molecular pathway and potential target in pancreatic adenocarcinoma. Pancreatology. 2012;12:372-9 pubmed publisher

Ayyanathan K, Kesaraju S, Dawson Scully K, Weissbach H. Combination of sulindac and dichloroacetate kills cancer cells via oxidative damage. PLoS ONE. 2012;7:e39949 pubmed publisher

Wanngren J, Ottervald J, Parpal S, Portelius E, Strömberg K, Borgegard T, et al. Second generation ?-secretase modulators exhibit different modulation of Notch ? and A? production. J Biol Chem. 2012;287:32640-50 pubmed

Moskowitz H, Gooding W, Thomas S, Freilino M, Gross N, Argiris A, et al. Serum biomarker modulation following molecular targeting of epidermal growth factor and cyclooxygenase pathways: a pilot randomized trial in head and neck cancer. Oral Oncol. 2012;48:1136-45 pubmed publisher

Zhu R, Cheng K, Mackenzie G, Huang L, Sun Y, Xie G, et al. Phospho-sulindac (OXT-328) inhibits the growth of human lung cancer xenografts in mice: enhanced efficacy and mitochondria targeting by its formulation in solid lipid nanoparticles. Pharm Res. 2012;29:3090-101 pubmed publisher

Yip Schneider M, Wu H, Hruban R, Lowy A, Crooks P, Schmidt C. Efficacy of dimethylaminoparthenolide and sulindac in combination with gemcitabine in a genetically engineered mouse model of pancreatic cancer. Pancreas. 2013;42:160-7 pubmed publisher

Zhu C, Cheng K, Ouyang N, Huang L, Sun Y, Constantinides P, et al. Phosphosulindac (OXT-328) selectively targets breast cancer stem cells in vitro and in human breast cancer xenografts. Stem Cells. 2012;30:2065-75 pubmed publisher

Manzano A, Perez Segura P. Colorectal cancer chemoprevention: is this the future of colorectal cancer prevention?. ScientificWorldJournal. 2012;2012:327341 pubmed publisher

Liu R, Dang W, Jianting M, Su C, Wang H, Chen Y, et al. Citalopram alleviates chronic stress induced depression-like behaviors in rats by activating GSK3? signaling in dorsal hippocampus. Brain Res. 2012;1467:10-7 pubmed publisher

Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W. Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). PLoS Comput Biol. 2011;7:e1002310 pubmed publisher

Hamza A, Zhao X, Tong M, Tai H, Zhan C. Novel human mPGES-1 inhibitors identified through structure-based virtual screening. Bioorg Med Chem. 2011;19:6077-86 pubmed publisher

Chen M, Vijay V, Shi Q, Liu Z, Fang H, Tong W. FDA-approved drug labeling for the study of drug-induced liver injury. Drug Discov Today. 2011;16:697-703 pubmed publisher

Gozalbes R, Jacewicz M, Annand R, Tsaioun K, Pineda Lucena A. QSAR-based permeability model for drug-like compounds. Bioorg Med Chem. 2011;19:2615-24 pubmed publisher

Schiefer I, Abdul Hay S, Wang H, Vanni M, Qin Z, Thatcher G. Inhibition of amyloidogenesis by nonsteroidal anti-inflammatory drugs and their hybrid nitrates. J Med Chem. 2011;54:2293-306 pubmed publisher

Yuan M, Luo M, Song Y, Xu Q, Wang X, Cao Y, et al. Identification of curcumin derivatives as human glyoxalase I inhibitors: A combination of biological evaluation, molecular docking, 3D-QSAR and molecular dynamics simulation studies. Bioorg Med Chem. 2011;19:1189-96 pubmed publisher

Ekins S, Williams A, Xu J. A predictive ligand-based Bayesian model for human drug-induced liver injury. Drug Metab Dispos. 2010;38:2302-8 pubmed publisher

Gozalbes R, Pineda Lucena A. QSAR-based solubility model for drug-like compounds. Bioorg Med Chem. 2010;18:7078-84 pubmed publisher

Fogli S, Banti I, Stefanelli F, Picchianti L, Digiacomo M, Macchia M, et al. Therapeutic potential of sulindac hydroxamic acid against human pancreatic and colonic cancer cells. Eur J Med Chem. 2010;45:5100-7 pubmed publisher

Greene N, Fisk L, Naven R, Note R, Patel M, Pelletier D. Developing structure-activity relationships for the prediction of hepatotoxicity. Chem Res Toxicol. 2010;23:1215-22 pubmed publisher

Prado Prado F, Garcia Mera X, González Díaz H. Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species. Bioorg Med Chem. 2010;18:2225-2231 pubmed publisher

Uehara T, Ono A, Maruyama T, Kato I, Yamada H, Ohno Y, et al. The Japanese toxicogenomics project: application of toxicogenomics. Mol Nutr Food Res. 2010;54:218-27 pubmed publisher

Guerra A, Campillo N, Paez J. Neural computational prediction of oral drug absorption based on CODES 2D descriptors. Eur J Med Chem. 2010;45:930-40 pubmed publisher

Fourches D, Barnes J, Day N, Bradley P, Reed J, Tropsha A. Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chem Res Toxicol. 2010;23:171-83 pubmed publisher

Moore R, Derry S, McQuay H. Single dose oral sulindac for acute postoperative pain in adults. Cochrane Database Syst Rev. 2009;:CD007540 pubmed publisher

Romeiro N, Leite R, Lima L, Cardozo S, de Miranda A, Fraga C, et al. Synthesis, pharmacological evaluation and docking studies of new sulindac analogues. Eur J Med Chem. 2009;44:1959-71 pubmed publisher

Ahlin G, Karlsson J, Pedersen J, Gustavsson L, Larsson R, Matsson P, et al. Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1. J Med Chem. 2008;51:5932-42 pubmed publisher

Pedersen J, Matsson P, Bergström C, Norinder U, Hoogstraate J, Artursson P. Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2). J Med Chem. 2008;51:3275-87 pubmed publisher

Romeiro N, Sant Anna C, Lima L, Fraga C, Barreiro E. NSAIDs revisited: putative molecular basis of their interactions with peroxisome proliferator-activated gamma receptor (PPARgamma). Eur J Med Chem. 2008;43:1918-25 pubmed publisher

Baert B, Deconinck E, Van Gele M, Slodicka M, Stoppie P, Bodé S, et al. Transdermal penetration behaviour of drugs: CART-clustering, QSPR and selection of model compounds. Bioorg Med Chem. 2007;15:6943-55 pubmed

Pelletier D, Gehlhaar D, Tilloy Ellul A, Johnson T, Greene N. Evaluation of a published in silico model and construction of a novel Bayesian model for predicting phospholipidosis inducing potential. J Chem Inf Model. 2007;47:1196-205 pubmed

Diamandis P, Wildenhain J, Clarke I, Sacher A, Graham J, Bellows D, et al. Chemical genetics reveals a complex functional ground state of neural stem cells. Nat Chem Biol. 2007;3:268-73 pubmed

Flis S, Soltysiak Pawluczuk D, Jedrych A, Jastrzebski Z, Remiszewska M, Splawinski J. Antiangiogenic effect of sulindac sulfide could be secondary to induction of apoptosis and cell cycle arrest. Anticancer Res. 2006;26:3033-41 pubmed

Aureli L, Cruciani G, Cesta M, Anacardio R, De Simone L, Moriconi A. Predicting human serum albumin affinity of interleukin-8 (CXCL8) inhibitors by 3D-QSPR approach. J Med Chem. 2005;48:2469-79 pubmed

. Exisulind: Aptosyn, FGN 1, Prevatac, sulindac sulfone. Drugs R D. 2004;5:220-6 pubmed

Kratochwil N, Huber W, Muller F, Kansy M, Gerber P. Predicting plasma protein binding of drugs: a new approach. Biochem Pharmacol. 2002;64:1355-74 pubmed

Tatebe S, Sinicrope F, Kuo M. Induction of multidrug resistance proteins MRP1 and MRP3 and gamma-glutamylcysteine synthetase gene expression by nonsteroidal anti-inflammatory drugs in human colon cancer cells. Biochem Biophys Res Commun. 2002;290:1427-33 pubmed

Haanen C. Sulindac and its derivatives: a novel class of anticancer agents. Curr Opin Investig Drugs. 2001;2:677-83 pubmed

Saso L, Valentini G, Casini M, Grippa E, Gatto M, Leone M, et al. Inhibition of heat-induced denaturation of albumin by nonsteroidal antiinflammatory drugs (NSAIDs): pharmacological implications. Arch Pharm Res. 2001;24:150-8 pubmed

Taylor M, Lawson K, Ignatenko N, Marek S, Stringer D, Skovan B, et al. Sulindac sulfone inhibits K-ras-dependent cyclooxygenase-2 expression in human colon cancer cells. Cancer Res. 2000;60:6607-10 pubmed

Williams C, Goldman A, Sheng H, Morrow J, DuBois R. Sulindac sulfide, but not sulindac sulfone, inhibits colorectal cancer growth. Neoplasia. 1999;1:170-6 pubmed

d Alteroche L, Benchellal Z, Salem N, Regimbeau C, Picon L, Metman E. [Complete remission of a mesenteric fibromatosis after taking sulindac]. Gastroenterol Clin Biol. 1998;22:1098-101 pubmed

Duffy C, Elliott C, O Connor R, Heenan M, Coyle S, Cleary I, et al. Enhancement of chemotherapeutic drug toxicity to human tumour cells in vitro by a subset of non-steroidal anti-inflammatory drugs (NSAIDs). Eur J Cancer. 1998;34:1250-9 pubmed

Waddell W. Stimulation of apoptosis by sulindac and piroxicam. Clin Sci (Lond). 1998;95:385-8 pubmed

Yoon K, Ng S. A case of sulindac-induced enteropathy resulting in jejunal perforation. Ann Acad Med Singapore. 1998;27:116-9 pubmed

Davies N, Watson M. Clinical pharmacokinetics of sulindac. A dynamic old drug. Clin Pharmacokinet. 1997;32:437-59 pubmed

Lione A, Scialli A. The developmental toxicity of indomethacin and sulindac. Reprod Toxicol. 1995;9:7-20 pubmed

Zundler J, Walker S. [Sulindac--drug therapy for familial adenomatous polyposis?]. Med Klin (Munich). 1993;88:35-8, 49 pubmed

Waddell W. The effect of sulindac on colon polyps: circumvention of a transformed phenotype--a hypothesis. J Surg Oncol. 1994;55:52-5 pubmed

Awaya N, Fujii T, Akizuki M. [Development of Stevens-Johnson syndrome following sulindac administration in a patient with mixed connective tissue disease]. Ryumachi. 1993;33:432-6 pubmed

Tonelli F, Valanzano R, Dolara P. Sulindac therapy of colorectal polyps in familial adenomatous polyposis. Dig Dis. 1994;12:259-64 pubmed

Waddell W, Miesfeld R. Adenomatous polyposis coli, protein kinases, protein tyrosine phosphatase: the effect of sulindac. J Surg Oncol. 1995;58:252-6 pubmed

Giardiello F. Sulindac and polyp regression. Cancer Metastasis Rev. 1994;13:279-83 pubmed

Duggan D. Sulindac: therapeutic implications of the prodrug/pharmacophore equilibrium. Drug Metab Rev. 1981;12:325-37 pubmed

Gallanosa A, Spyker D. Sulindac hepatotoxicity: a case report and review. J Toxicol Clin Toxicol. 1985;23:205-38 pubmed

Uchihara M, Maekawa S, Kobayashi T, Fukuma T, Sakai H, Shaura K, et al. [A case of sulindac induced acute pancreatitis]. Nihon Shokakibyo Gakkai Zasshi. 1992;89:2073-6 pubmed